


PHARMACEUTICAL 2019

Biostax Corp. Rank 356 of 363









PHARMACEUTICAL 2019

Biostax Corp. Rank 356 of 363



The relative strengths and weaknesses of Biostax Corp. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Biostax Corp. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 623% points. The greatest weakness of Biostax Corp. is the variable Assets, Current, reducing the Economic Capital Ratio by 297% points.

The company's Economic Capital Ratio, given in the ranking table, is -489%, being 526% points below the market average of 37%.

Input Variable	Value in 1000 USD
Assets, Current	89
Cost of Goods Sold	48
Intangible Assets	0
Liabilities, Current	11,342
Liabilities, Non-Current	0
Other Assets	0.20
Other Compr. Net Income	0
Other Expenses	774
Other Liabilities	0
Other Net Income	-4,541
Other Revenues	114
Property and Equipment	2.8
Research and Development	144
Selling, General and Administrative Expense	3,232

Output Variable	Value in 1000 USD
Assets	92
Liabilities	11,342
Expenses	4,198
Revenues	114
Stockholders Equity	-11,251
Net Income	-8,626
Comprehensive Net Income	-8,626
Economic Capital Ratio	-489%

